You are here

News

22.09.2014

Hepatitis C: Sit in of European patients to request access to new medicines, on occasion of the informal meeting of European Health Ministers in Milan

September 22nd, 2014

In support of the Call to EU Ministers of Health and CEOs of Abbvie, BMS, Gilead, Janssen and Merck/MSD regarding Universal Access to Curative Hepatitis C Treatment in the EU an beyond (attached), EPAC, Lila and Nadir with the support of the subscribers of the call, European Civil Society Forum on HIV/AIDS (CSF), European Aids Treatment Group (EATG), Aids Action Europe (AAE), European Liver Patients Association (ELPA), World Hepatitis Alliance (WHA), International Network of People who Use Drugs (INPUD), Correlation Network, Eurasian Harm Reduction Network (EHRN), European Harm Reduction Network (EHRN) and International Harm Reduction Association (IHRA) organize a “Sit-In” of people living with hepatitis C and their allies on the 22nd of September, at the Mico Conference Center, in Milan, starting at 11:20 am, to advocate for, and demand, a clear political and public health commitment and leadership from the twenty eight member states of the European Union and from the European Commission itself to:

- Ensure, that all patients in serious clinical situations have IMMEDIATE access to more effective therapeutic combinations of DAAs without interferon in compassionate, free use when there is no Market Introduction Authorization (MIA) and no current adequate alternatives;

- Commit publicly to provide treatment over the next fifteen years to all, with the best available combination therapies for the elimination of hepatitis C in a sustainable and affordable way in all European health care systems;

- Allocate financial and technical resources to prevent, diagnose and treat hepatitis C, with a view to its elimination;

- Invest in the diagnosis and referral to health care of all people living with hepatitis C;

- Promote evidence and human rights based drug policies that ensure the access of people who use drugs, the group most affected group by hepatitis C, to treatment;

- Engage in meaningful conversations with the pharmaceutical companies and involve community leaders, including representatives of organizations of people who use drugs, in the process of finding fast and sustainable solutions to providing universal access to hepatitis C treatment.

For further information please contact:

Ivan Gardini, EpaC - Associazione Onlus 

gardini@epac.it

Margaret Walker, European Liver Patients Association (ELPA)

Margaret@elpa-info.org

Chris Ward, European Aids Treatment Group (EATG)

chris.ward@eatg.org

Mobile: +447875436646


Share this Site

Twitter News